5-((6-chloropyridazin-3-yl)methyl)-2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazine | 1186482-08-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-((6-chloropyridazin-3-yl)methyl)-2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazine
• 英文别名: 5-(6-Chloro-pyridazin-3-ylmethyl)-2-(2,3-difluoro-phenyl)-5H-imidazo[4,5-d]pyridazine；5-[(6-chloropyridazin-3-yl)methyl]-2-(2,3-difluorophenyl)imidazo[4,5-d]pyridazine
• CAS: 1186482-08-5
• 化学式: C₁₆H₉ClF₂N₆
• 分子量: 358.737
• InChiKey: BYJCXJWQRUVUDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  69.4
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5-((6-chloropyridazin-3-yl)methyl)-2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazine 、 2,3-二甲氧基苯硼酸 生成 2-(2,3-Difluoro-phenyl)-5-[6-(2,3-dimethoxy-phenyl)-pyridazin-3-ylmethyl]-5H-imidazo[4,5-d]pyridazine
  参考文献：
  名称：

  ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE

  摘要：

  本发明涉及公式（I）的化合物和组合物，其药学上可接受的盐和溶剂化物，以及其制备和用于治疗由Flaviviridae病毒家族中的病毒至少部分介导的病毒感染的用途。

  公开号：

  US20090226398A1
• 作为产物：
  描述：

  2,3-二氟苯甲醛 在 N-氯代丁二酰亚胺 、 硫酸 、 烟酰胺 、 二异丁基氢化铝 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.58h， 生成 5-((6-chloropyridazin-3-yl)methyl)-2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazine
  参考文献：
  名称：

  Imidazopyridazine Hepatitis C Virus Polymerase Inhibitors. Structure–Activity Relationship Studies and the Discovery of a Novel, Traceless Prodrug Mechanism

  摘要：

  By reducing the basicity of the core heterocycle in a series of HCV NS5B inhibitors, the hERG liability was reduced. The SAR was then systematically explored in order to increase solubility and enable dose escalation while retaining potency. During this exploration, a facile decarboxylation was noted and was exploited as a novel prodnig mechanism. The synthesis and characterization of these prodrugs and their utilization in chronic toxicity studies are presented.

  DOI：

  10.1021/jm401337x

文献信息

• Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them
  申请人：Leivers Martin Robert

  公开号：US20100029655A1

  公开（公告）日：2010-02-04

  Disclosed are processes for the preparation of compounds of formula I and compositions that comprise said compounds of formula I. Also disclosed are processes for the preparation of compounds of formula III and compositions that comprise said compounds of formula III.

  公开了制备公式I化合物的过程以及包含所述公式I化合物的组合物。 还公开了制备公式III化合物的过程以及包含所述公式III化合物的组合物。
• [EN] DERIVATIVES OF IMIDAZO [4, 5-D] PYRIDAZINE AND THEIR USE AS ANTI-VIRAL COMPOUNDS<br/>[FR] DÉRIVÉS D'IMIDAZO[4,5-D]PYRIDAZINE ET LEUR UTILISATION EN TANT QUE COMPOSÉS ANTIVIRAUX
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009111501A1

  公开（公告）日：2009-09-11

  Disclosed are compounds and compositions of Formula (I), pharmaceutically acceptable salts and solvates thereof, and their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.
• ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
  申请人：Leivers Martin Robert

  公开号：US20090226398A1

  公开（公告）日：2009-09-10

  Disclosed are compounds and compositions of Formula (I), pharmaceutically acceptable salts and solvates thereof, and their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.

  披露了公式(I)的化合物和组合物、药物可接受的盐和溶剂化物，以及它们的制备和使用，用于治疗至少部分由黄病毒科病毒家族中的病毒介导的病毒感染。
• Imidazopyridazine Hepatitis C Virus Polymerase Inhibitors. Structure–Activity Relationship Studies and the Discovery of a Novel, Traceless Prodrug Mechanism
  作者：Martin Leivers、John F. Miller、Stephanie A. Chan、Ryan Lauchli、Sebastian Liehr、Wenyan Mo、Tony Ton、Elizabeth M. Turner、Michael Youngman、J. Greg Falls、Susan Long、Amanda Mathis、Jill Walker

  DOI：10.1021/jm401337x

  日期：2014.3.13

  By reducing the basicity of the core heterocycle in a series of HCV NS5B inhibitors, the hERG liability was reduced. The SAR was then systematically explored in order to increase solubility and enable dose escalation while retaining potency. During this exploration, a facile decarboxylation was noted and was exploited as a novel prodnig mechanism. The synthesis and characterization of these prodrugs and their utilization in chronic toxicity studies are presented.